NSPR News and Press, InspireMD Inc. From 05/16/23

- Completed transformational private placement for up to $113.6 million, including $42.2 million upfront - - Generated Q1 2023 CGuard EPS revenue of $1.2 million, an increase of 6.7% over Q1 2022 despite the temporary expiration of the Company’s CE Mark certification until mid-Marc...

2023-05-15 08:35:34 ET InspireMD ( NASDAQ: NSPR ) signed a securities purchase agreement with certain healthcare-focused institutional investors that have agreed to provide up to $113.6M in gross proceeds to InspireMD through a private placement that includ...

Led by Marshall Wace with participation from OrbiMed, Rosalind, Nantahala, Soleus, Velan and certain InspireMD Board members $42.2 million financing upfront with up to an additional $71.4 million tied to exercise of milestone-driven warrants TEL AVIV...

- Conference call and webcast to be held at 8:30 a.m. EDT - TEL AVIV, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, an...

-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel, May 05, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, anno...

Procedure performed as part of the company’s ongoing CGuardians U.S. Investigational Device Exemption (IDE) trial designed to support potential U.S. marketing approval of the CGuard stent system CGuardians enrollment on track to be completed by the end of Q2 2023 TEL AVIV, ...

TEL AVIV, Israel, April 27, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report first quarter 2023 financial results ...

2023-03-30 10:34:05 ET InspireMD, Inc. (NSPR) Q4 2022 Earnings Conference Call March 30, 2023 8:30 AM ET Company Participants Chuck Padala - IR, LifeSci Advisors Marvin Slosman - CEO Craig Shore - CFO Conference Call Participants Benjamin Haynor - All...

2023-03-30 07:04:50 ET InspireMD press release ( NASDAQ: NSPR ): Q4 GAAP EPS of $0.60 beats by $1.44 . Revenue of $1.03M (-25.4% Y/Y) beats by $0.03M . As of December 31, 2022, cash, cash equivalents and short-term bank deposits were $17.8 million compared to $...

- 2022 CGuard EPS revenue of $5.1 million increased 18.9% over 2021 - - Resumed shipments of CGuard EPS to CE Mark territories under the pre-existing Medical Device Directive (MDD) regulatory framework; Company anticipates re-certification under new Medical Device Regulation (MRD) f...